Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|October 30, 2009

Sartorius Opens New Plant in India

Author(s)Chitra Sethi

In a ribbon-cutting ceremony held on October 30, 2009, Sartorius (Goettingen, Germany) inaugurated its new plant at the Sartorius Group's location in Bangalore, India.

In a ribbon-cutting ceremony held on October 30, 2009, Sartorius (Goettingen, Germany) inaugurated its new plant at the Sartorius Group's location in Bangalore, India. The new facility is designed to supply the Indian marketplace and additional Asian markets.

CEO Joachim Kreuzburg, Arnold Picot, supervisory board chairman, and Amit Chatterjee, managing director of Sartorius India, officially started up operations at the large building complex. At its new site, Sartorius has combined its five decentralized individual locations in Bangalore into a single new plant on premises, thus creating new capacity for the company's Indian business in both Group divisions.

The company's expanded capacity in India enables it to create and develop new process technologies and to custom-tailor these to meet customers' individual process requirements, according to the company press release.

Among other products, Sartorius in Bangalore, India, develops and manufactures bioreactors and additional equipment for pharmaceutical customers, laboratory equipment, as well scales and other weighing equipment for industrial applications.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.